Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
- Conditions
- Cutaneous LupusSystemic Lupus Erythematosus (SLE)Juvenile SLE
- Interventions
- Registration Number
- NCT03122431
- Lead Sponsor
- University of Sao Paulo General Hospital
- Brief Summary
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness. Within this context, this project aims to evaluate the importance of monitoring blood levels and salivary drug used in rheumatic autoimmune diseases in the monitoring of adherence to therapy. In addition, this project intends to use the monitoring of drug levels, based on pharmacokinetic studies and pharmacokinetics/pharmacodynamics modeling, to broaden the understanding of the possible cellular, tissue and immunological mechanisms involved in efficacy and adverse effects of these drugs with the prospect of reducing the damage and maintain therapeutic efficacy. The high-performance liquid chromatography (HPLC) coupled to mass spectrometry, which will be used to evaluate hydroxychloroquine, thalidomide, glucocorticoids, is considered the gold standard technology to qualitative and quantitative analysis of drugs in blood and its comparison with the dosage in the saliva is an improvement in simplification of the process. For biological agents the focus will be on the understanding the loss of efficacy and the possible role of anti-TNF antibodies using ELISA capture methodology.This project will be divided into four sections with their respective sub-projects according to the medications that will be studied: hydroxychloroquine, thalidomide, biologic agents and glucocorticoids.
- Detailed Description
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness. There is also a large inter-individual variability in response to treatments with regard to efficacy and toxicity, and for many drugs, there is also a period of weeks to months to establish its efficacy. Within this context, this project aims to evaluate the importance of monitoring blood levels and salivary drug used in rheumatic autoimmune diseases in the monitoring of adherence to therapy. In addition, this project intends to use the monitoring of drug levels, based on pharmacokinetic studies and pharmacokinetics/pharmacodynamics modeling, to broaden the understanding of the possible cellular, tissue and immunological mechanisms involved in efficacy and adverse effects of these drugs with the prospect of reducing the damage and maintain therapeutic efficacy. The high-performance liquid chromatography (HPLC) coupled to mass spectrometry, which will be used to evaluate hydroxychloroquine, thalidomide, glucocorticoids, is considered the gold standard technology to qualitative and quantitative analysis of drugs in blood and its comparison with the dosage in the saliva is an improvement in simplification of the process. The implementation of this methodology dedicated to research in our center, with the necessary training of human resources, will enable the standardization and availability of this advanced technology to other muldisciplinary projects in various areas of science. For biological agents the focus will be on the understanding the loss of efficacy and the possible role of anti-TNF antibodies using ELISA capture methodology.This thematic project will be divided into four sections with their respective sub-projects according to the medications that will be studied: hydroxychloroquine, thalidomide, biologic agents and glucocorticoids.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 93
- SLE diagnosis according to 1997 ACR criteria
- Active and refractory cutaneous lupus lesions
- Male gender (using contraceptive barrier method) or confirmed infertility for female gender
- Normal electroneuromyography at study entry
- Alcoholism
- History of peripheral neuropathy
- Previous history of thrombophilia or positive antiphospholipid antibodies
- Renal and/or central nervous system and/or hematological activity
HCQ reduced subproject:
Inclusion Criteria:
- SLE diagnosis according to 1997 ACR criteria
- Use of hydroxychloroquine (5 to 6.5mg/kg/day) for ≥5 years
- SLEDAI-2K <4
Exclusion Criteria:
- Alcoholism
- Renal dialysis
- Concomitant infectious process
- Acute and chronic liver diseases
- Concomitant use of some drugs that interact with HCQ (cimetidine, antacids, digoxin, aminoglycosides, penicillamine, neostigmine, pyridostigmine)
- Signs of Retinopathy
HCQ high subproject:
Inclusion Criteria:
- SLE diagnosis according to 1997 ACR criteria
- No use of hydroxychloroquine for ≥ 6 months
- LES/LESJ in activity (SLEDAI≥6)
Exclusion Criteria:
- Alcoholism
- Renal dialysis
- Concomitant infectious process
- Acute and chronic liver diseases
- Concomitant use of some drugs that interact with HCQ (cimetidine, antacids, digoxin, aminoglycosides, penicillamine, neostigmine, pyridostigmine)
- Signs of Retinopathy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Inactive SLE with standard dose of HCQ standard dose of HCQ This subproject includes one arm of lupus patients with inactive disease, in which will be maintained on standard dose of Hydroxychloroquine (400mg/day). Inactive SLE with reduced dose of HCQ Hydroxychloroquine reduced This subproject includes one arm of lupus patients with inactive disease: in which the dose will be reduced to 400mg 3 times a week (Hydroxychloroquine reduced). SLE/cutaneous lupus with thalidomide Thalidomide This subproject includes only one arm of lupus patients with active and refractory cutaneous disease and eligible for Thalidomide 100mg/day for 12 months.
- Primary Outcome Measures
Name Time Method Serum Levels of Thalidomide 12 months Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS)
Serum Levels of Hydroxycloroquine 12 months Serum levels of hydroxycloroquine by LCMS
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hospital das Clinicas da Faculdade de Medicina da USP
🇧🇷São Paulo, Brazil